Picture of Wimbledon Clinics

Wimbledon Clinics

Trial Evaluates New Approach To Treating Tendon Injuries

Contact us for an appointment

*At Wimbledon Clinics we comply with the provisions of the General Data Protection Regulations (GDPR) and the Data Protection Act (UK). We will never share your data without your permission and we will only use your data how you’ve asked us to. Please let us know if you’d like to join our mailing list to receive updates about our specialist consultants, the latest treatments for orthopaedic and sports injuries and prevention tips for common injuries.

For more information, click here to view our privacy policy

Scientists in Glasgow are investigating a potential new therapy for the treatment of tendon injuries, such as tennis elbow and Achilles tendinitis.

This type of injury, also known as tendinopathy, accounts for a significant proportion of all sporting injuries – as much as 30-50%, according to the University of Glasgow. The new approach could encourage healing of damaged tendons.

Healthy tendons are primarily composed of type-1 collagen, a very strong material. In response to injury, the body produces the inferior type-3 collagen to quickly repair the damage. This type of collagen is not as strong as type-1 and is more prone to damage, but over time it is usually replaced by the stronger type-1.

As the University of Glasgow explains, in some cases repetitive damage means the body never replaces the weaker type-3 collagen. As a result, these people are left with inherently weaker tendons and long-term symptoms, such as pain and reduced mobility.

A new trial will use injections of microRNA – small molecules that help regulate gene expression – into the tendon to ‘dial-down´ the production of type-3 collagen and switch to type-1.

Neal Millar, an academic consultant orthopaedic surgeon and clinical senior research fellow at the University of Glasgow, commented: “Tendinopathy is essentially the result of an imbalance between collagen type-1 and type-3 and we have discovered the molecular cause. This breakthrough has allowed us to find a way to alter the levels of collagen type-3 in tendons, with the ultimate aim to get patients with tendon injuries better quicker.”

Co-investigator and senior molecular biologist Dr Derek Gilchrist added: “Our studies have revealed the previously unrecognised ability of a single microRNA to cross-regulate important functions in the early biological processes that lead to tissue repair.”

Results of previous studies by the team have been published in Nature Communications, revealing the role of the microRNA 29a in tendon tissue repair.